John Troyer

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.